

Clinical Policy: Rucaparib (Rubraca)

Reference Number: ERX.SPA.11

Effective Date: 04.01.17

Last Review Date: 02.22

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Rucaparib (Rubraca[®]) is a poly (ADP-ribose) polymerase (PARP) inhibitor.

FDA Approved Indication(s)

Rubraca is indicated:

Ovarian cancer

- For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Prostate cancer

- For the treatment of adult patients with a deleterious *BRCA* mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.

This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions[™] that Rubraca is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Ovarian Cancer (must meet all):

1. Diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer;
2. Prescribed by or in consultation with an oncologist;
3. Age \geq 18 years;
4. For Rubraca requests, member must use rucaparib, if available, unless contraindicated or clinically significant adverse events are experienced;
5. Prescribed as a single agent;
6. Member meets one of the following (a or b):*
 - a. FDA approved use: Completion of \geq 2 platinum-based (e.g., carboplatin, cisplatin, oxaliplatin) chemotherapy regimens* with complete or partial response;
 - b. Off-label NCCN recommended use: Documented deleterious germline and/or somatic *BRCA* mutation, and failure of \geq 2 lines of chemotherapy* (see Appendix B), unless all are contraindicated or clinically significant adverse effects are experienced;
7. Member has not previously received a PARP inhibitor (e.g., Lynparza[®], Talzenna[®], Zejula[®]) (see Appendix D);

**Prior authorization may be required*

8. Request meets one of the following (a or b):*
 - a. Dose does not exceed 1,200 mg (4 tablets) per day;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Commercial – Length of Benefit

Medicaid – 6 months

B. Prostate Cancer (must meet all):

1. Diagnosis of metastatic CRPC as evidenced by disease progression despite androgen deprivation therapy (ADT) (*see Appendix D*);
2. Prescribed by or in consultation with an oncologist or urologist;
3. Age \geq 18 years;
4. Documented deleterious germline and/or somatic BRCA mutation;
5. For Rubraca requests, member must use rucaparib, if available, unless contraindicated or clinically significant adverse events are experienced;
6. Prescribed concurrently with systemic ADT (*see Appendix D*) or member has had a bilateral orchiectomy;
7. Failure of both of the following, unless clinically significant adverse effects are experienced or all are contraindicated (a and b):
 - a. A taxane-based regimen (e.g., docetaxel);*
**Prior authorization may be required for taxanes*
 - b. Abiraterone (Zytiga®), unless member has previously failed Yonsa® (abiraterone) or Xtandi® (enzalutamide);*
**Prior authorization may be required for Zytiga, Yonsa, and Xtandi*
8. Member has not previously received a PARP inhibitor (e.g., Lynparza, Talzenna, Zejula) (*see Appendix D*);
9. Request meets one of the following (a or b):*
 - a. Dose does not exceed 1,200 mg per day (4 capsules per day);
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Commercial – Length of Benefit

Medicaid – 6 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions, or documentation supports that member is currently receiving Rubraca for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. For Rubraca requests, member must use rucaparib, if available, unless contraindicated or clinically significant adverse events are experienced;
4. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 1,200 mg (4 tablets) per day;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Commercial – Length of Benefit

Medicaid – 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.
Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ADT: androgen deprivation therapy
BRCA: breast cancer susceptibility gene
CRPC: castration resistant prostate cancer
FDA: Food and Drug Administration

GnRH: gonadotropin-releasing hormone
LHRH: luteinizing hormone-releasing hormone
NCCN: National Comprehensive Cancer Network
PARP: poly (ADP-ribose) polymerase

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Ovarian Cancer: examples of chemotherapy agents		
Alimta® (pemetrexed)	Varies	Varies
Alkeran® (melphalan)		
Avastin® (bevacizumab)		
carboplatin (Paraplatin®)		
cisplatin (Platinol-AQ®)		
cyclophosphamide (Cytosan®)		
docetaxel (Taxotere®)		
doxorubicin (Doxil®, Adriamycin®)		
etoposide (Vepesid®)		
gemcitabine (Gemzar®)		
ifosfamide (Ifex®)		
irinotecan (Camptosar®)		
oxaliplatin (Eloxatin®)		
topotecan (Hycamtin®)		
Hexalen® (altretamine)		
paclitaxel		
Prostate Cancer		
docetaxel	75 mg/m ² IV for 6 cycles	Varies
abiraterone (Zytiga®, Yonsa®)	Zytiga: 1,000 mg PO BID in combination with prednisone	1,000 mg QD; 1,000 mg BID if taking a strong CYP3A4 inducer
	Yonsa: 500 mg PO QD in combination with methylprednisolone	Yonsa: 500 mg QD; 500 mg BID if taking a strong CYP3A4 inducer
enzalutamide (Xtandi®)	160 mg PO QD	160 mg/day; 240 mg/day if taking a strong CYP3A4 inducer

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

- CRPC is prostate cancer that progresses clinically, radiographically, or biochemically despite castrate levels of serum testosterone (< 50 ng/dL). Per the NCCN, androgen deprivation therapy (ADT) should be continued in the setting of CRPC while additional therapies are applied.
- Examples of ADT include:
 - Bilateral orchiectomy (surgical castration)
 - Luteinizing hormone-releasing hormone (LHRH; also known as GnRH) given with or without an anti-androgen:
 - LHRH agonists: Zoladex[®] (goserelin), Vantas[®] (histrelin), leuprolide (Lupron Depot[®], Eligard[®]), and Trelstar[®] (triptorelin)
 - Anti-androgens: bicalutamide (Casodex[®]), flutamide, nilutamide (Nilandron[®]), Xtandi[®] (enzalutamide), Erleada[®] (apalutamide)
 - LHRH antagonist: Firmagon[®] (degarelix), Orgovyx[®] (relugolix)
- There are insufficient data regarding the use of consecutive PARP inhibitors. Most PARP inhibitor pivotal trials excluded prior PARP inhibitor use. The NCCN does not make any explicit recommendations in this regard (other than for ovarian cancer, where it states data is limited), and there are no randomized controlled trials evaluating such use.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Ovarian cancer	600 mg PO BID	1,200 mg/day
Metastatic CRPC	600 mg PO BID. Patients receiving Rubraca should also receive a GnRH analog concurrently or should have had bilateral orchiectomy	1,200 mg/day

VI. Product Availability

Tablets: 200 mg, 250 mg, 300 mg

VII. References

1. Rubraca Prescribing Information. Boulder, CO: Clovis Oncology, Inc.; June 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209115s009lbl.pdf. Accessed June 24, 2022.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed June 24, 2022.
3. National Comprehensive Cancer Network. Ovarian Cancer Version 1.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed June 24, 2022.
4. National Comprehensive Cancer Network. Prostate Cancer Version 1.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed October 4, 2021.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q18 annual review: Added age ≥ 18 years per PI. Updated Appendix B with additional acceptable prior treatment regimens based on NCCN Ovarian Cancer guidelines.	11.13.17	02.18
Criteria added for new FDA indication: maintenance treatment of ovarian cancer which is in complete/partial response to platinum-based chemotherapy; references reviewed and updated.	05.29.18	08.18

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2019 annual review: no significant changes; references reviewed and updated.	11.20.18	02.19
1Q 2020 annual review: no significant changes; added quantity limit of 4 tablets for max dosing; added Medicaid line of business with 6/12 month approval durations; references reviewed and updated.	10.29.19	02.20
Criteria added for new FDA indication: metastatic CRPC; for both indications, added requirement against prior use of a PARP inhibitor; added Appendix D; references reviewed and updated.	06.15.20	08.20
1Q 2021 annual review: oral oncology generic redirection language added; for ovarian cancer, single-agent therapy clarification added; RT4: mCRPC label update to require FDA-approved diagnostic test - no change to mCRPC indication; references reviewed and updated.	11.14.20	02.21
1Q 2022 annual review: no significant changes; references reviewed and updated.	10.04.21	02.22
RT4: treatment of BRCA-mutated ovarian cancer after 2 or more therapies changed to off-label usage due to FDA withdrawal but still supported by NCCN; revised oral oncology generic redirection language.	06.23.22	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2017 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.